Form 4: SpringWorks Therapeutics COO Badreddin Edris Sells Shares
SEC Form 4
Badreddin Edris, Chief Operating Officer of SpringWorks Therapeutics, executed multiple sales of common stock on March 3, 2025, under a pre-arranged trading plan.
Summary
- On March 3, 2025, Badreddin Edris, the Chief Operating Officer of SpringWorks Therapeutics, sold shares of common stock.
- The sales were executed under a Rule 10b5-1 trading plan adopted on February 29, 2024.
- A total of 19,990 shares were sold in multiple transactions at varying prices.
- The weighted average sale prices ranged from $53.1218 to $56.2025 per share.
- Following the reported transactions, Edris directly owns 169,712 shares of SpringWorks Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting stock sales by an insider. It doesn't inherently convey positive or negative sentiment, as the sales were pre-planned.
Industry Context
Form 4 filings are a routine part of the US stock market and are required by the SEC to ensure transparency when company insiders trade their company's stock. It is not possible to determine the motivation of the seller from the document.
Key Dates
| Date | Description |
|---|---|
| February 29, 2024 | Date of adoption of the Rule 10b5-1 trading plan |
| March 3, 2025 | Date of the stock sale transactions |
| March 5, 2025 | Date of the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.